Sexually Transmitted Diseases

At CROI 2018, Dr. Helen Weiss highlighted where we are in terms of meeting these goals, where the challenges are, and strategies to help prevent new infections.

In an oral abstract session at CROI 2018, Dr. Nathan Thielman stresses that understanding the interest of HIV-positive treatment-experienced individuals in new antiretroviral therapies may help inform their development and uptake.

Better understanding of the vaginal microbiome may provide new insights into HIV acquisition.

Study results revealed that dolutegravir appears to be effective and well-tolerated in HIV/tuberculosis (TB) co-infected adults also receiving rifampin-based TB therapy.

First detailed analysis by race and risk group finds that two-thirds of those who could benefit from PrEP are African American or Latino, but they account for the smallest percentage of prescriptions to date.

Week 48 safety results show that switching to B/F/TAF was noninferior to remaining on DTG/ABC/3TC.

Week 24 safety and efficacy data on women who switched from a baseline regimen (SBR) to B/F/TAF were presented at CROI 2018.

More research is needed but characterizing the biologic risk factors associated with HIV that are specific to transgender women may be key to informing more effective preventive strategies.

Research suggests misperceptions about the risk of HIV infection should be corrected at the time of testing, with PrEP initiated same-day if appropriate.

Although antiretroviral therapy has led to significantly longer life expectancies among individuals with HIV, this, in turn, has contributed to the likelihood that these individuals will develop age-related comorbidities at earlier ages.

International interdisciplinary collaboration will bring us that much closer to a cure for HIV.

Contagion® will be providing exclusive coverage on the conference, and so, keep your eyes peeled for session coverage and interviews with some of the key presenters.

NIAID Vaccine Research Center scientists alters broadly neutralizing HIV antibody to make it last longer in the blood.

Infectious disease physicians often have to fight to garner the attention of policymakers.

The investigators concluded that 2 separate immune pathways are key players in the way in which the body deals with chlamydia: one pathway clears the bacteria, while another fuels inflammation and tissue damage.

A panel of experts in a recent symposium discuss how dental professionals can play an integral role in increasing HPV vaccination rates and decreasing HPV-related cancer.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

FDA recommends that health care providers practice caution before prescribing clarithromycin to patients with heart disease due to potentially fatal long-term risks.

PrEP does not have to be taken daily to be effective, but consistency and a strong support system are key.

A recent study finds a potential link between cannabis use and possible beneficial reduction in systemic inflammation and immune activation in ART-treated HIV patients.

Mylan NV's new drug application for its combo regimen of dolutegravir, emtricitabine, and tenofovir alafenamide, received tentative approval from the US Food and Drug Administration under the President's Emergency Plan for AIDS Relief (PEPFAR).

A recent CDC report finds those between 15 and 44 years of age are significantly more likely to have never been tested for HIV.

Advances in antiretroviral therapies increase opportunities for patients with HIV to have more successful treatment outcomes.

ViiV Healthcare has launched a phase 3 study to assess if adults with HIV-1 who have achieved viral suppression on a 3-drug regimen can maintain suppression when switched to a 2-drug regimen.

The FDA has granted pre-market approval for a new HPV test that can detect and identify HPV genotypes that put women at increased risk for cervical cancer.